Stat 3蛋白在原发性支气管肺癌组织中的表达及其临床意义

Expression of Stat 3 protein in lung carcinoma and its clinical significance

目的 :分析 Stat 3蛋白的表达与肺癌临床分型、分期及 P5 3蛋白、增殖细胞核抗原 (PCNA )表达的关系 ,探讨 Stat 3蛋白在肺癌发病机制中的作用。方法 :用免疫组化二步法检测 42例原发性支气管肺癌组织中 Stat 3蛋白、P5 3蛋白和 PCNA的表达。 结果 :肺癌组织中 Stat 3蛋白的阳性率为 81.0 % ;Stat 3蛋白在肺癌组织中的表达与 T、N分期和临床分期无关 ,而与肺癌组织类型相关 ,非小细胞肺癌的表达明显高于小细胞肺癌 ;Stat 3蛋白与 P5 3蛋白及 PCNA的表达呈显著正相关。 结论 :Stat3蛋白在肺癌组织中有异常表达 ,它可能参与肺癌细胞中 p5 3基因的调节 ,促进肺癌细胞增殖 ,此信号转导与转录激活因子可能在肺癌的发生发展中有重要作用 ,抑制 Stat3蛋白通路有望成为一条治疗肺癌的新途径。

Objective: To analyze the relationship between Stat 3 protein expression and clinical staging, tissue types, P53 protein and PCNA in lung carcinoma, and to investigate the role of Stat 3 protein in the pathogenesis of lung carcinoma. Methods: Using immunohistochemical technique, Stat 3 protein, P53 protein and PCNA were detected in different tissue in 42 patients with lung carcinoma without radiotherapy and chemotherapy. Results: The positive rate of Stat 3 was 81.0% in lung carcinoma. The expression intensity of Stat 3 in lung carcinoma was not associated with T,N and clinical stage , but it was associated with the expression intensity of P53 and PCNA and it was related to tissue types.Stat 3 protein were markedly higher in NSCLC than that in SCLC. Conclusion: The expression of Stat 3 protein is abnormal in lung carcinoma. Stat 3 may involve in regulation of p53 gene in lung carcinoma cell and accelerate proliferation of lung carcinoma cell, it may play an important role in generation of lung carcinoma. Inhibition of Stat 3 pathways may become a new therapy for lung carcinoma.